What this shows
Market trades first
This view focuses on purchases and sales with reported trade value. Lower-signal rows are moved out of the first screen, not hidden.
Ticker page
RPRX Insider Trading Activity
Track Royalty Pharma plc (RPRX) insider transactions, SEC Form 4 filings, insider buys, insider sales, filing dates, trade values, and source links. Recent summary: 10 trades, 0 buys, and 0 sales. Learn more
Feed status Last SEC check:Loading Last Filing: Loading
View RPRX
Access Free feed
Quick read What does this view show?
Why it matters
Use it as the default scan
Start here when you want the newest activity that most retail investors expect from an insider trading feed.
How to read it
Open the full ledger when needed
Use All Form 4 Filings when you want grants, exercises, gifts, conversions, and every normalized row.
Stacked feeds
Key insider views at a glance
Filings
RPRX Form 4 filing history
Status Loading
Latest visible filing loading.
Public Form 4 filings, normalized for cleaner scanning. What do these codes mean?
Cluster detail
Cluster members
Ticker context
Ticker summary
Recent insider activity for this company.
Insider detail
Insider activity
Recent transactions grouped by reporting owner.
Filters
Filters
Latest news
RPRX headlines
- Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) · Jun 15, 2026
- This Royalty Pharma Insider Reduced Their Stake By 10% · Jun 12, 2026
- 3 Unpopular Stocks We’re Skeptical Of · Jun 12, 2026
- Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report? · Jun 10, 2026
- Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? · Jun 9, 2026
Plain-English summary
RPRX insider activity summary
Royalty Pharma plc (RPRX) insider activity over the recent reporting window shows no qualifying Form 4 activity in the recent window. Market data shows a current price of $53.70 and a market capitalization of $31.38B. Blue Collar Picks normalizes public SEC Form 4 filings into a research-friendly view organized by ticker, insider role, transaction type, filing date, and reported value. RPRX pages are designed as a research starting point, not investment advice. Verify the original SEC filing, read the transaction code, compare the trade against the insider's role and history, and consider whether the activity is an open-market purchase, a sale, a grant, an option exercise, or another lower-signal filing type before drawing conclusions.
Company snapshot
Royalty Pharma plc at a glance
Context
Earnings & analyst view
Earnings
Aug 4, 2026
Analyst View
$59.25 +8.72% upside
Target range $46.00–$66.00.
Ownership context
Top institutional holders
| Holder | Shares | % Held | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 43,571,633 | 0.10% | $2.37B | Mar 31, 2026 |
| Capital International Investors | 35,005,736 | 0.08% | $1.91B | Mar 31, 2026 |
| Blackrock Inc. | 25,907,745 | 0.06% | $1.41B | Mar 31, 2026 |
| FMR, LLC | 25,152,242 | 0.06% | $1.37B | Mar 31, 2026 |
| BAILLIE GIFFORD & CO | 16,155,677 | 0.04% | $880.5M | Mar 31, 2026 |
Primary source
Verify with the original SEC filings
Blue Collar Picks normalizes public Form 4 records but the SEC filing is the source of record. Use the original filing before making any investment decision.
Open RPRX Form 4 filings on SEC EDGAR → See insider trading stocks ranked by activity → Read the Blue Collar Picks methodology → Read the investment disclaimer →
Weekly recap
Get the easier version in your inbox.
Start with the free weekly recap. Upgrade later if you want the paid daily brief.
Free weekly recap. No login required. Unsubscribe any time.
Method Public Form 4 filings, normalized for cleaner scanning. Filtered rows stay available in All Form 4 Filings and ticker history. Which view should I use? →
Paid research tools
CSV exports are becoming a paid feature.
Join the waitlist for founding-member access to CSV exports, saved screens, and premium download tools when they open.